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Abstract
The care and condition of people with cystic ﬁbrosis (CF) in 34 European countries is reported using data obtained from publications,
registries and professionals providing CF patient care. Care and outcomes differ markedly between countries. Although the 2005 European
standards of patient care publication was widely known, in many countries there were no specialized CF centres. In only a minority of
countries was funding considered adequate and in some countries costs covered by patients compromised care. Only 15 countries had a
national CF patient registry. Neonatal screening was routine in only 10 countries, but this included 59% of European infants. The initiatives of
EuroCareCF Workpackage 1 to form networks for professionals working with CF patients are described. Suggestions for the future include at
least one adequately staffed CF Centre in each country, improved funding, neonatal screening, national patient registries and the formation of
national CF parent and patient organisations.
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1. Introduction
Advances in patient care have led to dramatic improve-
ments in prospects for cystic ﬁbrosis (CF) patients; in many
countries most individuals are now expected to reach adult-
hood. However, the burden of care remains high. Management
requires a close collaboration between specialists from differ-
ent ﬁelds to maximise longevity and quality of life (QoL).
The primary objective of Workpackage 1 (WP1) of the
EuroCareCF project was to optimise patient care and CF
teamwork, ensuring parity and equity of access to services
across all countries in the European Union (EU). The purpose
of this paper is to describe the extent to which these objectives
have been achieved.
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2. Inﬂuence of standard of care on health and survival
It has become apparent that the progressive deterioration
of respiratory function described in the older CF literature
is not inevitable. If respiratory infection is identiﬁed early
and repeatedly eradicated by appropriate antibiotic treatment,
chronic infection with both Staphylococcus aureus and Pseu-
domonas aeruginosa can be prevented or certainly delayed
for many years [1–3]. Also the early malnutrition and later
growth problems can be avoided or minimised when enzyme
supplements and nutritional intervention are started soon after
birth [4]. To achieve this for all infants with CF, neonatal
screening followed by early diagnosis, close monitoring and
effective treatment is mandatory – the last is essential to
achieve beneﬁt from early diagnosis [5].
3. Central role of CF centre care
There is general agreement that advice on treatment and
management is best provided by a multidisciplinary team at
a CF centre [6–9]. The CF team also has the responsibility
to undertake clinical audit and research in a condition, such
as CF, where treatment is continually changing, improving
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and becoming increasingly more effective. In practice, this
is best accomplished by a team at a CF centre where many
people with CF are treated. Indeed, all signiﬁcant advances
in treatment have occurred at CF centres where there are
sufﬁcient patients and staff to recognise and investigate
problems. It is also important that the results of care are
assessed over the long term. Pulmonary damage, either
sustained before diagnosis or caused by suboptimal treatment
after diagnosis, can be contained with intensive modern
treatment for a few years [10,11]. However, this damage
will eventually result in a more rapid decline in pulmonary
function during adolescence or early adult life.
The main principles of treatment are now readily available
to those treating people with CF. However, it appears to be
the ﬁne details of management, which may differ between CF
centres that account for some of the signiﬁcant differences
in the welfare of patients. For example, most studies that
correlate treatment received with clinical condition indicate
that more frequent monitoring of a CF patient’s clinical status,
including measurements of lung function and respiratory cul-
tures leads to more frequent treatment, especially with intra-
venous antibiotics, which in turn maintains good health [12].
4. Publications, guidelines and standards
The past 20 years have seen a great increase in all types
of published information relating to CF. Medline citations
increased from 7,622 in the decade between 1986 and 1995
to 11,396 between 1996 and 2005; already there are a further
5,194 since 2006. Moreover, between 1966 and 1997 there
was a 30-fold increase in CF clinical trials of which over a
third were only reported at meetings [13]. Between 1998 and
2002, another 261 CF clinical trials took place [14].
In an attempt to ensure that patients receive the most
appropriate and acceptable treatment, various patients’ and
professional organisations, with the help of expert committees,
have produced their own standards for general care as well
as more detailed guidelines for speciﬁc aspects of treatment
[8,9,15]. These publications provide guidance for those with
less experience and ensure that members of CF patient teams
give consistent advice to patients and carers. In addition, these
publications indicate to providers the facilities and level of
funding required. In 2005, the main concepts of the standards
of care for people with CF were reviewed in the European
Cystic Fibrosis Society’s “Standards of care for patients with
cystic ﬁbrosis: A European consensus” [9].
5. Standards of care for people with cystic ﬁbrosis: a
European consensus
In March 2004, a 2-day European Cystic Fibrosis Society
(ECFS) consensus meeting was held in Artimino, Italy on
Standards of Care for People with Cystic Fibrosis. The 34
members of the consensus group were from 17 European
countries and North America. The role of a CF centre was
discussed as well as the staff required. The routines for CF
patient care were agreed including outpatients, inpatients,
annual reviews, details of various aspects of care, including
the recently diagnosed patient, the patient diagnosed in adult
life and atypical patients. The importance and role of other
specialists in CF patient care were detailed. The document
ﬁnished with 35 practical questions, the answers to which
were agreed by the consensus group. The conclusions of the
consensus meeting were published in the Journal of Cystic
Fibrosis in 2005 [9].
Thus, the ECFS consensus group achieved their aim of
deﬁning standards for the routine evaluation, monitoring and
treatment of people with CF. If adopted by all European CF
centres, these consensus guidelines would provide a quality
assurance instrument and a basis for the audit of CF care.
There have also been European consensus groups to con-
sider antibiotic therapy [16,17], nutrition [18], immunisation
[19], the management of pregnancy [20], mutation analysis
[21] and neonatal screening [5,22].
6. Standards of care in Europe as represented by an early
survey in 2005/6
The European standards of care for people with CF was
published in 2005 [9] and provided criteria for deﬁning a CF
centre and the roles of the individual professional members of
the CF patient care team. Since 2000, there had been earlier
European consensus publications (see above Section 5). In
2005/6, a survey was undertaken which asked questions on
general care and infection management; the results of this
survey were published in 2009 [23,24]. The questionnaire was
sent to a heterogeneous group of professionals who were all
members of the ECFS; they were identiﬁed from the Society’s
mailing list. There was a disappointing response to the
survey with only 177 of 544 (33%) completed questionnaires
returned. Analysis of those returned revealed “a high degree
of implementation of the European Consensus Guidelines”
and identiﬁed “areas of improvement to include shared
care, access to care and funding inequalities” [23]. With
regard to the control and treatment of infection, the authors
concluded that the European Consensus Guidelines were
widely adhered to. Areas for improvement included “initiating
therapy for exacerbations early, separating infected patients
and optimizing the duration of antibiotic therapy” [24]. We
agree with the authors that, in view of the poor response to the
survey, the results might overestimate the extent of adherence
to guidelines and standards of care – clinics familiar with the
guidelines and following the standards being more likely to
respond. Of note, there was a striking difference in the rate of
response from countries in Eastern and Western Europe with
the UK, France, Germany and Italy providing approximately
half of all the responses; only 12% were from Eastern Europe.
7. Collection of documents on standards of care by WP1
of EuroCareCF (2007–2009)
One of the initiatives of EuroCareCF WP1 was the
collection of information regarding CF patients especially
documents produced in various European countries indicating
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the extent to which ECFS standards of care had already been
implemented. Analysis of the collected documents would pro-
vide information about the present status of CF patient care in
Europe. It was also anticipated that the existence of standard
documents relating to CF patient care would provide some
indication of the experiences of the multi-disciplinary CF
teams in Europe and the quality of patient care they provided.
It was decided to contact colleagues in various European
countries either by e-mail or directly during ECFS con-
ferences. The collection of the documents proved to be a
very demanding task and required more time and effort than
anticipated.
Nevertheless, information from a total of 34 European
countries was collected The number of people with CF
resident in each of these countries was derived from national
registries (available in 15 countries), from estimations by local
CF physicians or paediatricians or from previous publications
[44]. Overall, there were a total of 39,897 people with CF
who were treated in 32 European countries (Table 1). The
countries having their own national documents relating to CF
care are reported in Table 2.
A ﬁrst analysis of the collected information relating to the
standard documents and other data from the various European
countries has been summarised (for further information, see
Tables 1 and 2).
Fifteen countries were aware of and used the ECFS
Standards of Care document even though they did not have
a national document of their own. However, 6 countries did
not consider that their practice followed ECFS standards for
a variety of reasons, including stafﬁng and facilities or small
patient numbers. In 11 countries, the extent of use of the
ECFS Standards of Care document was not determined.
We endorse the production of national consensus guide-
lines to develop and consolidate a national approach. Hope-
fully, the more advanced CF centres and clinics would
favourably inﬂuence the standard of care in those clinics with
less experience and facilities. A national approach would also
be more likely to result in adequate national government
funding for CF care. It is this model of development we
would endorse to ensure equity of care because it involves
and motivates health professionals to actively implement the
Care Standards.
8. Differences in the Standard of Care between European
countries is still very wide
There are many examples of suboptimal provision of
facilities and care for people with CF for which there are a
number of reasons. For many years, it has been known that
outcomes between countries differ signiﬁcantly [25]. In North
America, there were even signiﬁcant differences between
patient outcomes at accredited CF Centres [26,27]. These
differences are still obvious in many regions and appear to be
due to the type and intensity of care that CF patients receive
[12,28,29]. In recent years, differences in patient outcomes in
various CF centres have received a considerable amount of
attention particularly in the United States [30,31].
CF professionals in virtually all European countries stated
that the ECFS document on standards of care for CF
patients [9] was well known and being implemented in
many countries. However, our survey revealed that in at
least 10 European countries the fundamental concept of a
“Specialized CF Centre” based on the integrated action of
a multidisciplinary team is either non-existent or far from
being applied. The following examples from various clinics
illustrate the problems:
• “Importance (of physiotherapists) is underrated by the
doctors. No trained nutritionists in any centre – teams do
not exist”
• “In some centres there is only the doctor. Specialized
physiotherapists and dietitians are missing. Dietitians only
in some centres
• “No CF team”
• “No CF centres”
• “Some physiotherapy, few dietitians. Doctors give advice”
• “Essentially only pediatricians”
The lack of a CF centre team is almost certainly one of the
major factors adversely affecting the care of many people with
CF. As discussed above, centre care delivered by a team of
professionals, who spend much of their time treating people
with CF, is probably the most important single factor that has
improved the care and outlook of people with CF over the
years [6–8,32–36].
An almost unanimous view of those providing CF patient
care is that funding made available for CF services was
inadequate to provide the standard of care and facilities
recommended in the ECFS document on standards of care
for CF patients [9]. In only 2 of 21 countries where an
opinion on the adequacy of funding for CF staff was obtained,
were funding levels regarded as adequate (Netherlands and
France). In the remaining 19 countries, funding was regarded
as inadequate or not speciﬁcally intended for CF staff.
As previously reported by Elborn et al. [23], the predomi-
nant funding provider of CF centres and clinics is the national
healthcare system of the country. However, the proportion of
care cost covered by CF patients may at times compromise
their treatment. This more frequently is the case for adults
with CF. In 13 European countries, treatment was free; in 10
countries, some payment was required for certain medicines
(e.g. vitamins and dietary supplements) and in 4 countries,
the treatment of children was free, but adults were required
to contribute to the cost of their treatment. However, in most
countries the parents’ or patients’ contribution to the cost
of their treatment was relatively modest when set against
the total cost of treatment. Nonetheless, in certain instances
it might have been one of the factors contributing to why
CF patients received suboptimal care or were denied more
expensive and effective treatments [24].
9. The importance of CF patient registries
A CF registry or database is essential if national ﬁgures
are required for monitoring patients’ treatment and outcomes.
For many years, it has been appreciated that patient registries
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Table 1
Demographics of the European CF population
Country Population People Prevalence Incidence Median age Percentage of patients Median age of Percentage of
×1000 with CF per 10,000 (years) >18 years death (years) expected if
>16 years (Median survival) survival normal
Austria 8,210 680 0.828 1 :3,500 14.8 42.86 29
Belgium 10,414 1,057 1.015 1 :2,850 17.4 49.3 30.2 29
51.9
Bulgaria 7,204 192 0.266 1 :3,250 33 20 9
Cyprus 797 26 0.338 1 :7,914 26
Czech Republic 10,212 570 0.558 1 :2,833 14.7 38.3 24.6 16
Denmark 5,501 450 0.819 1 :4,700 18.9 52.28 39
Estonia 1,299 40 0.308 1 :7,500 23
Finland 5,250 64 0.127 1 :25,000 31
France 62,151 4,533 0.729 1 :4,348 15 41.3 23.5 32
Germany 82,330 6,835 0.829 1 :3,300 19.1 50.4 23.7 27
43.4 (37.4)
Greece 10,737 555 0.517 1 :3,500 18
Hungary 9,906 580 0.586 1 :4,000 20 23
Ireland 4,203 1,182 2.81 1 :5,353 17 49 24 38
Italy 58,126 5,064 0.871 1 :4,238 16.5 22.3 37
Latvia 2,232 30 0.134 1 :3,300 26 4
Lithuania 3,555 47 0.276 1 :6,000 8
Luxembourg 492 40 0.813
Malta 405 23 0.467
Netherlands 16,716 1,275 0.763 1 :4,750 17.1 33 36
Poland 38,483 1,000 0.26 1 :5,000 17 18.7 6
Portugal 10,708 285 0.266 1 :6,000 16
Romania 22,215 238 0.107 1 :2,056 20 2
Slovakia 5,463 416 0.761 1 :1,800 11
Slovenia 2,006 66 0.329 1 :3,000 10
Spain 40,281 2,750 0.679 1 :3,750 21
Sweden 9,060 620 0.684 1 :5,600 18.8 56 38
United Kingdom 61,113 8,513 1.393 1 :2,381 18 27 33
56.2 (38.8)
Croatia 4,489 108 0.241 1 :3,300 17.2 8
Macedonia 2,067 110 0.532 1 :3,980 9.5 20
Turkey 76,806 600 0.078 1 :3,000 2
Iceland 307 7 0.228 1 :8,344 19
Norway 4,661 274 1.030 1 :8,642 21.3 27.8 51
63.5
Russia 140,041 2,200 0.64 1 :10,080 16
Israel 7,234 510 0.774 17.04 43
Sources of data are listed at the end of the main text.
Data for Bulgaria and Finland taken from Farrell [44].
Median age of survival was available for a minority of countries and is bracketed below the median age of death.
are essential to determine both outcomes and the appropriate
funding required to provide an adequate service [12]. Fortu-
nately, recent data are increasingly available for a number of
European countries that have their own national CF registries
[37–42].
Of 32 European countries where recent information was
available, only 15 had a national CF registry; in 17 countries
there was no current registry. Seventeen countries had submit-
ted some patient data to the European CF Patient Registry in
2007, but from 4 countries the data were from only one CF
centre and in some instances patient numbers fell below those
estimated by local clinicians. Sixteen countries did not submit
any data to the European CF Patient Registry in 2007 (Dr HV
Olesen, personal communication). Undoubtedly, the lack of
reliable pan-European data on CF is a major handicap to the
monitoring of changes in patient treatment and care.
For many countries, there are no basic national data
for prevalence of the condition, for median survival and
median age of death of people with CF. So, the success of
the European CF Patient Registry is of central importance,
indeed essential, for the improvement of CF patient care [43].
Unfortunately, the collection of national patient data on this
scale is time-consuming, expensive and difﬁcult to achieve in
clinics where staff are overworked and may fail to appreciate
the ultimate beneﬁts to their patients of time spent in this way.
10. Many European countries do not have outcome data
on their patients
The present study was not designed (nor are the data of
adequate accuracy) to compare the survival or median age
of death in various European countries. However, the data
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Table 2
Treatment of European CF population
Country Neonatal Number of Centres with National Follow Adequate Funding of Cost to National Data to
screening CF centres >50 patients guidelines ECFS stafﬁng? CF care? families and CF ECFS
available? standards? patients? Registry? Registry?
Austria YES 4 4 YES YES NO GOV NIL YES YES
Belgium NO 7 7 NO YES NO GOV NIL YES YES
Bulgaria NO 4 1 NO GOV SOME YES YES
Cyprus NO 0 0 NO NO YES
Czech Republic YES 4 YES NO NO GOV SOME YES YES
Denmark NO 2 2 YES YES NO GOV NIL YES YES
Estonia 2 0 NO NO NO
Finland NO 0 0 NO NO NO NO
France YES 49 49 YES YES YES GOV SOME YES NO
Germany NO 93 36 YES YES NO INS NIL YES YES
Greece NO 8 4 YES GOV NIL NO YES
Hungary NO 12 4 YES YES NO GOV NIL YES YES
Ireland YES 13 NO GOV NIL YES YES
Italy YES 28 24 NO YES NO GOV NIL YES YES
Latvia NO 1 0 NO YES NO GOV ADULTS/SOME NO NO
Lithuania NO 0 0 NO NO NIL NO NO
Luxembourg NO 0 0 NO GOV SOME NO NO
Malta NO 1 0 Brompton YES YES GOV NIL NO NO
Netherlands NO 7 7 YES YES YES INS+GOV SOME YES YES
Poland YES 10 4 YES NO NO GOV SOME NO NO
Portugal NO 5 3 NO YES NO GOV NIL NO YES
Romania NO 6 2 NO NO GOV ADULTS/SOME YES YES
Slovakia YES 6 4 YES NO NO INS SOME NO NO
Slovenia 0 0 NO NO YES
Spain YES 27 20 NO YES GOV NIL NO NO
Sweden NO 4 4 YES YES NO GOV SOME YES YES
Max.   180 p.a.
United Kingdom YES 48 38 YES YES NO GOV ADULTS/SOME YES YES
Croatia NO 5 1 YES NO NO HOSPITAL SOME YES YES
Macedonia NO 1 1 NO NO INS+GOV SOME NO NO
Turkey NO 7 NO GOV/UNIV ADULTS/SOME NO NO
Iceland NO 1 0 NO NO GOV NIL NO NO
Norway NO 2 2 YES YES NO GOV SOME NO NO
Max   250 p.a.
Russia YES 42 YES GOV YES
Israel NO 7 6 NO YES GOV SOME YES YES
Abbreviations: Brompton, Royal Brompton Hospital, London; GOV, government; INS, insurance; UNIV, university. See text for further information.
reported by individual clinicians closely involved in CF care
suggest that there is signiﬁcant variation in both facilities and
outcomes in different European countries. The median age
of patients, the percentage of patients who are 16 years and
over and the median age of death would all be expected to
increase as CF patient care in a country improves. Recent data
demonstrate obvious differences between countries particu-
larly between those in Western and Eastern Europe conﬁrming
an urgent need for improvements in CF patient care in several
areas of Europe [43].
Those countries with well established CF centres and large
patient populations had median patient ages of between 15 and
19 years. The median age of death all over Europe varied from
9.5 to 27 years and the percentage of patients over 16 to 18
years from approximately 17 to 56% (Table 1). Unfortunately,
there was so little information on median survival that the
ﬁgures can only be taken as a very approximate indicator of
the situation. Nevertheless, there appears to be an association
between large patient numbers and the presence of CF centres
and a greater proportion of older patients and an increased
median survival.
The marked variation in reported incidence of CF (range
1:1,800 in Slovakia to 1:25,000 in Finland) probably, not
only reﬂects the frequency of CF mutations in the population,
but also problems in the detection of the disease in many
countries where there is no neonatal CF screening [44].
Where neonatal screening has been introduced, the incidence
is likely to be more accurate. This is suggested by the relation
between the reported incidence rate of CF and the existence
of a neonatal screening program: most of the 9 countries
with a relatively infrequent incidence rate of CF of 1:5,000
or above had no neonatal screening program in recent years.
In some countries where there is no neonatal screening, the
likely incidence of CF has also been estimated from studies
examining the carrier rate of CF mutations in the population
[45]. The knowledge of the presence of a single mutation in a
person with symptoms suggestive of CF can also lead to over
diagnosis [46].
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11. The relationship of prevalence to incidence
As a relatively crude indicator of the standard of CF care,
and thus survival, in a particular country, the relationship
between the estimated incidence at birth, the number of
people with CF surviving and the total population may give
some broad indication of their fate. One assumes that the
incidence at birth would remain the same throughout life if
the disease was completely controlled and all survived as did
the unaffected population. The percentage below this expected
incidence (total population divided by incidence) would give
some indication of the chances of survival. We have calculated
this for countries where adequate data are available. It appears
that a larger proportion of the infants with CF survive in
countries where the care facilities appear to be more adequate
– for example in some countries nearly 40% of the expected
number survive, whereas in other countries, less than 10%
survive (Table 1).
12. Neonatal screening for CF
Early diagnosis is an important issue that has been con-
sidered as part of the activities of EuroCareCF Workpackage
3. Our survey revealed that although national neonatal CF
screening is performed in only 10 of 34 countries, some 59%
of the European population is screened. In 2 of these 10
countries only certain regions undertake neonatal screening.
Although the evidence of the beneﬁts of neonatal screening,
with early diagnosis and treatment, are now well documented,
it is important to emphasize that to achieve these beneﬁts,
early diagnosis must be followed by a high standard of CF
care. If this care is not available, it is unlikely that neonatal
screening will have a signiﬁcant favourable effect on either
the health or survival of affected children [47].
It is interesting that some of the countries with major CF
centres and recognised excellent outcomes such as Denmark,
Netherlands, Belgium, Sweden and Israel have not yet intro-
duced national neonatal CF screening. Nonetheless, evidence
of early chest involvement is accumulating [48] and while
good care will minimise the short and medium effects of
early pulmonary damage [10], in the absence of neonatal
screening some infants will not be diagnosed until extensive
irreparable damage to the lungs has occurred. It is likely that
this early damage will be irreversible and progressive and
will eventually compromise long term health and survival. It
is increasingly obvious that neonatal CF screening, diagnosis
and intensive treatment will be required to achieve the best
results. This will be essential when treatments for the basic
defect become available.
13. Difﬁculties with providing CF care in some European
countries
There are a number of examples where there is great
difﬁculty in delivering a standard of care which in any way
approaches that recommended by the ECFS. In Latvia, for
example, up until the 1970s, the mean duration of survival
did not exceed 1–2 years. CF specialists from Sweden made
a major contribution to improvements in the survival of
Latvian CF patients, by providing the latest ideas about CF
patient management and a great deal of advice and practical
experience from the Stockholm CF Centre. Inhalators and
medicine were brought as humanitarian aid. The median age
of survival is presently 22 years in Latvia.
A consistent problem in Eastern European countries is the
lack of CF centres as deﬁned by the European consensus
[9], with an associated lack of a multidisciplinary CF care
team. There are in addition frequent problems in obtaining
medicines and other treatment devices free of charge for
patients. There are few transplantation programs, and patients
are referred to other countries for transplantation (mostly to
Vienna, Austria).
14. Actions carried out by EuroCareCF WP1 to improve
the situation
Another task of EuroCareCF WP1 was to establish net-
works for each clinical care speciality:
• The network of physicians was established initially with
the help of the ECFS of which most paediatricians and
physicians working in the CF ﬁeld across Europe are
members. Thus, ECFS membership lists were invaluable
in establishing contacts with CF doctors to set up Euro-
CareCF activities and allowed us to develop the physicians’
network including countries of Eastern Europe (376 physi-
cians and paediatricians from over 30 countries joined the
network).
• Information on the network for physiotherapists was ob-
tained from the membership list of IPG-CF (International
Physiotherapy Group for Cystic Fibrosis; www.cfww.org/
ipg-cf/). This professional group is organized as follows:
there are 5 people on the board and approximately 60
contact persons from European countries (about 2 per
country).
• A network for CF nurses has been in existence for a
number of years, with 204 nurses coming from European
countries.
• The psychologists/psychiatrists network has 37 European
members, but just 4 are from Eastern European countries.
Also social workers have been included, as a subgroup, in
this network.
• The dieticians/nutritionists network has 35 members from
Europe, including both dieticians and physicians.
• Currently an international network for pharmacists does
not exist.
The existence of a network of National CF Associations
(CF Europe) has had the effect of improving communication
with those involved in CF patient care.
Finally, training grants were provided by WP1 of Euro-
CareCF to send a professional involved in the care of CF pa-
tients to a speciﬁc institution or to attend a specialized course
to receive further training. Alternatively, training grants were
used to bring an experienced CF team member to a speciﬁc
CF centre to give specialist training to a group of trainees.
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15. Future perspective and actions
There are few conditions where outcome is so dependent
on treatment and where treatment is so complex, time
consuming, changing and improving all the time. There are
obvious and signiﬁcant differences between the standard of
care delivered and outcomes for people with CF in various
European countries; obviously expectations differ in various
countries. Some of the means to be considered to achieve a
more uniform standard of good CF patient care are as follows:
• One or more teams of CF professionals in each country
should be identiﬁed that would form a nucleus of expertise
to demonstrate and spread the principles of good practice.
These would be sited in one or more of the large cities
where there is the possibility of attracting a substantial
number of patients. A nucleus of dedicated staff with a
signiﬁcant proportion of their time devoted to CF care and
a clinic of ideally more than 50 patients are essentials to
develop a high standard of CF care and improve services
– in fact, to develop a CF centre, for without such a
development it is unlikely care will improve.
• Special consideration should be given to small clinics
which, of necessity, will always have few patients (e.g.
Malta, Cyprus, and Iceland). Some form of shared care
with regular visits by CF specialist from a major centre, as
now occurs between Malta and the Royal Brompton Hos-
pital in London, as well as for Latvia and the Stockholm
CF Centre, would be a reasonable compromise.
• Sufﬁcient funding to support the CF staff and facilities
at a CF centre must be achieved. Although the physical
facilities in the hospital and outpatients are important, it is
the staff and their time, knowledge and sufﬁcient patients,
which are essential to improve the service. Some speciﬁc
actions were taken to urge politicians and administrators
allocating money and resources to establish CF teams
according to the ECFS document on standards of care
for CF patients [9]. For example, during the V4-CF
Conference (Kraków, Poland, 20–22 November 2008)
detailed discussions were held about the priorities for
allocation of funding, staff resources, facilities and devices.
During a public ceremony, the document listing the agreed
priorities was signed by physicians, local representatives
of CF Patient Organizations, the President of CF Europe
and the leader of WP1 on behalf of EuroCareCF. This
document was then presented to policy makers in each
of the Visegrad Group of countries (Czech Republic,
Hungary, Poland and Slovakia) and its progress then
followed-up by local patient organizations. In addition,
during their visit to the CF Centre at Košice, Slovakia,
the CF care team from Göteborg, Sweden took part in a
meeting with local hospital authorities to discuss how to
implement a proper CF Team dealing with the shortage
of resources, but also relying on the experience of other
countries. It is not possible to force any country or even
any hospital to undertake actions without being sensitive
to their circumstances. Only effective lobbying of hospital
administrators and government policy makers will lead to
success. This means understanding that making available
resources at the beginning leads to the saving of resources
later in terms of survival and quality of life of patients,
their families and society as a whole.
• Obviously supporting services such as microbiology, bio-
chemistry, clinical physiology and medical physics are
very important, but will only develop if there is demand for
their services (i.e. if there are sufﬁcient patients).
• Early diagnosis is important and neonatal screening should
be introduced at the same time as CF centres are estab-
lished. Screening if not followed by good care is of little
beneﬁt.
• Although our survey did not examine the treatments avail-
able to patients, it is likely that the cost of the particularly
expensive treatments will prove to be a continuing problem
in some countries. However, if treatment of chest infection
is early and vigorous and combined with the early intro-
duction of physiotherapy and mucolytic treatment, chronic
infection may be prevented for many years. As a result,
the need for more expensive treatments is considerably
reduced [40].
• It is essential that CF centres have a patient registry and
that they submit their patient data to both national and
European CF Registries. Only then will their progress be
monitored, outcomes compared and the need for changes
identiﬁed. The collection of data is time consuming and the
immediate rewards for staff involved are often not obvious.
• Training visits are of major importance and should be en-
couraged. Visits by professionals from developing centres
to established centres are preferable to established teams
from major centres visiting smaller developing clinics – a
practice which may seriously affect the work at the major
centre, in the case of smaller teams where there is just one
member for each speciality. If the staff from the developing
clinic visit an established centre, they can see not only the
team in action, attend CF clinics, ward rounds and team
meetings, but also meet all other professionals involved
in the care of CF patients, including microbiologists,
biochemists and radiologists.
• Readily available publications such as the ECFS consensus
documents are obviously appreciated and familiar to many
professionals treating people with CF. It must be stressed
that the basic principles of good CF care remain much
the same apart from the greater precautions to avoid cross
infection in recent years.
• CF parent and patient associations are essential and should
be encouraged. In collaboration with CF professionals,
these associations have a major role in improving care.
In many countries with reasonably developed CF services,
they have been responsible for many major advances
in care and can act as a pressure group on the health
authorities and Government. The UK CF Trust is a good
example of such an organisation that has been responsible
for or initiated many of the advances in CF care in the UK.
A national CF organisation, working with professionals
who provide care, acts as a permanent force to improve
treatment and facilities.
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16. Conclusions
It is crucial not to waste all the enthusiasm and work
undertaken by EuroCareCF participants and as a consequence
of the training grants ﬁnanced by EuroCareCF. However,
future programmes have to take into account the great amount
of work that remains outstanding. It is encouraging that there
are many people with a very high level of commitment to
improving the care of people with CF. It is also important that
scientiﬁc interests are encouraged. Members of EuroCareCF
WP1 are available for facilitating contacts between all the
members of the CF community and colleagues in different
countries of which names and e-mail addresses have been
collected for the specialist networks developed by WP1. This
is a source for contacts and mutual exchanges. Changing
social, economic and health management issues is by no
means easy, but it may become possible with the leadership
and co-ordinated efforts of the many skilled and experienced
colleagues in our continent.
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